Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
3+2 Pharma LLC
Agastiya Biotech LLC
Aileron Therapeutics Inc
Circle Pharma Inc
Dicer Pharmaceuticals Inc
Entrada Therapeutics Inc
f5 Therapeutics Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
MD2 Biosciences Inc
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology, Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
AB-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense Ri Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Beta catenin Degrader Antibody - Drug Profile
Product Description
Mechanism Of Action
Beta-Catenin Transcriptiol Complex Inhibitors - Drug Profile
Product Description
Mechanism Of Action
CBP/beta-Catenin Antagonist - Drug Profile
Product Description
Mechanism Of Action
History of Events
exisulind - Drug Profile
Product Description
Mechanism Of Action
FOG-001 - Drug Profile
Product Description
Mechanism Of Action
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRP - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Beta Catenin for Colorectal Cancer and Brain Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CTNNB1 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
ST-316 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Wnt-Driven Diseases - Drug Profile
Product Description
Mechanism Of Action
WNTinib - Drug Profile
Product Description
Mechanism Of Action
WX-024 - Drug Profile
Product Description
Mechanism Of Action
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Sep 08, 2022: Propanc Biopharma reports significant effects of PRP against the tumor microenvironment
Aug 23, 2022: Propanc Biopharma synthesizes recombint trypsinogen & chymotrypsinogen via POP1 joint research & drug discovery program
Jul 28, 2022: Propanc Biopharma’s CSO reflects on unique anti-cancer effects of PRP discovered over past decade
Jul 12, 2022: Propanc Biopharma’s CEO believes lead asset could unlock value as PRP advances to phase I, first-in-human study in advanced cancer patients
Jul 05, 2022: Propanc Biopharma’s CEO comments on the 39 granted patents and 26 patent applications under examition in key global jurisdictions
Jun 22, 2022: Propanc Biopharma’s CSO hails dostarlimab’s impressive results whilst acknowledging more work to be done in the fight against cancer
Jun 01, 2022: Propanc Biopharma believes PRP reduced toxicity will impact cancer patient lives significantly
May 26, 2022: Propanc Biopharma presents 100 years of clinical evidence for “novel” enzyme therapeutic approach to treat cancer
May 18, 2022: Propanc Biopharma undertaking PRP manufacturing & development for human use
May 11, 2022: Propanc Biopharma offers a novel way to stop cancer
May 03, 2022: Agastiya Biotech receives FDA Orphan Drug Desigtion for AB001 for pancreatic cancer and Acute Myeloid Leukemia (AML)
May 02, 2022: Propanc Biopharma purchases pharma grade raw materials for PRP manufacture in preparation for phase I first-in-human study
Apr 13, 2022: Propanc Biopharma’s magement explains why they believe cancer patients are likely to respond to PRP treatment
Apr 11, 2022: Sapience Therapeutics presents late-breaking data on ST316 at AACR 2022
Mar 22, 2022: Propanc Biopharma receives notice of allowance for method to treat cancer stem cells from the US Patent & Trademark Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)